Xeris Biopharma Holdings, Inc.
XERS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867096
In the last 90 days, Xeris Biopharma Holdings, Inc. insiders filed 0 open-market purchases and 10 sales; 242 institutions reported holding it in 13F filings for Q2 2026, worth $857.1M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Xeris Biopharma Holdings, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 111
- +6 vs. Q2 2023
- Shares held
- 55.0M
- −972.2K (−1.7%) vs. Q2 2023
- Total value
- $102.3M
- −$44.4M (−30.2%) vs. Q2 2023
- New holders
- 16
- 36 more added
- Sold out
- 10
- 25 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XERS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 242 | $857.1M |
| Q1 2026 | 239 | $610.3M |
| Q4 2025 | 227 | $792.0M |
| Q3 2025 | 231 | $789.3M |
| Q2 2025 | 201 | $422.9M |
| Q1 2025 | 199 | $480.9M |
| Q4 2024 | 162 | $222.2M |
| Q3 2024 | 144 | $182.2M |
| Q2 2024 | 135 | $136.6M |
| Q1 2024 | 142 | $133.7M |
| Q4 2023 | 120 | $140.8M |
| Q3 2023 | 111 | $102.3M |
| Q2 2023 | 105 | $146.7M |
| Q1 2023 | 92 | $80.6M |
| Q4 2022 | 97 | $71.6M |
| Q3 2022 | 101 | $89.3M |
| Q2 2022 | 103 | $91.3M |
| Q1 2022 | 103 | $129.2M |
| Q4 2021 | 92 | $120.2M |
| Q3 2021 | 71 | $42.9M |
| Q2 2021 | 94 | $114.9M |
| Q1 2021 | 103 | $149.7M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Xeris Biopharma Holdings, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 1,022,040 | $1.90M | 0.00% | +163,346+19.0% | Added |
| Redmile Group, LLC | 1,046,587 | $1.95M | 0.09% | 00.0% | Unchanged |
| Northern Trust Corp | 1,145,217 | $2.13M | 0.00% | −8,566−0.7% | Reduced |
| Millennium Management LLC | 2,274,144 | $4.23M | 0.00% | +463,797+25.6% | Added |
| State Street Corp | 2,570,122 | $4.78M | 0.00% | +25,224+1.0% | Added |
| Geode Capital Management, LLC | 2,773,293 | $5.16M | 0.00% | +91,488+3.4% | Added |
| MPM Oncology Impact Management LP | 3,987,967 | $7.42M | 1.98% | +12,968+0.3% | Added |
| Caxton Corp | 5,641,920 | $10.5M | 39.87% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 5,915,372 | $11.0M | 3.65% | +415,144+7.5% | Added |
| Vanguard Group Inc | 7,026,164 | $13.1M | 0.00% | +74,565+1.1% | Added |
| BlackRock Inc. | 9,374,242 | $17.4M | 0.00% | +39,646+0.4% | Added |
| EAM Investors, LLC | 0 | $0 | 0.00% | −757,962−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −127,091−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −80,416−100.0% | Sold out |
| Franklin Resources Inc | 0 | $0 | 0.00% | −63,703−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −44,839−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −25,800−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −11,393−100.0% | Sold out |
| O'Dell Group, LLC | 0 | $0 | 0.00% | −3,316−100.0% | Sold out |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Sofos Investments, Inc. | 0 | $0 | 0.00% | −3−100.0% | Sold out |